Business Context and Reporting Period
This Form 8-K is filed by OCIS, Inc. (Nevada) for the reporting period of August 30, 2005, covering events occurring on August 29, 2005. The registrant's principal executive office is located in Salt Lake City, Utah. Note: The filing metadata references "ABVC BIOPHARMA, INC.", but the document text explicitly identifies the registrant as OCIS, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
On August 29, 2005, OCIS Corp. was informed by its President, Brent W. Schlesinger, that he will resign effective December 31, 2005. Mr. Schlesinger will transition to a consultant role through February 2006 to assist with management transition. There are no reported disputes regarding his departure.
Outlook, Risks, and Management Commentary
Management has not yet decided on a replacement for Mr. Schlesinger, who was the principal behind the company's business plan and operations. The filing explicitly states that without Mr. Schlesinger, the direction of the business is in question and the ability to continue operations may be in jeopardy. Management intends to use the coming months to evaluate the best direction for the company's business and operations.
Investor Verification Checklist
- Verify the current operational status of OCIS, Inc. given the stated jeopardy to continued operations.
- Confirm whether a successor to President Brent W. Schlesinger has been appointed since the filing date.
- Review subsequent filings for updates on the company's strategic direction and business plan.
- Clarify the discrepancy between the metadata company name (ABVC BIOPHARMA, INC.) and the registrant name in the text (OCIS, Inc.).